Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (DE:LLY)
XETRA:LLY
Earnings Data
Report Date
Feb 11, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
6.09Last Year’s EPS
4.62Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a strong quarter with significant revenue growth, increased market share, and notable FDA and EU approvals. However, the company faced challenges with price declines in the U.S. and increased expenses. Despite these challenges, the overall sentiment is positive due to the strong financial performance and strategic advancements.Company Guidance
Record Revenue Growth
Revenue grew 54% compared to the same period last year, driven by key products. Gross margin as a percentage of revenue was 83.6%, an increase of 1.4 percentage points versus the same quarter last year.
Increased Market Share in Incretin Analogs
In the U.S., Lilly gained market share in the incretin analogs market for the fifth consecutive quarter. Lilly medicines account for nearly 6 out of 10 prescriptions within this large and growing class.
FDA and EU Approvals
U.S. FDA approval for imlunestrant under the brand name Inluriyo for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer. The EU approved Kisunla for early symptomatic Alzheimer's disease.
Strong International Performance
Revenue in Europe increased by over 100% in constant currency, and Japan, China, and the Rest of the World delivered constant currency revenue growth of 24%, 22%, and 51%, respectively.
R&D Advancements
Positive results from multiple Phase III trials for orforglipron in obesity and type 2 diabetes. Plans to initiate 2 Phase III trials with baricitinib in type 1 diabetes.
Manufacturing Expansion
Plans to build 2 new U.S. facilities for active pharmaceutical ingredients and the expansion of an existing facility in Puerto Rico.
DE:LLY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:LLY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 30, 2025 | €711.60 | €728.00 | +2.30% |
Aug 07, 2025 | €643.27 | €548.98 | -14.66% |
Feb 06, 2025 | €796.80 | €843.42 | +5.85% |
Oct 30, 2024 | €827.86 | €762.46 | -7.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Eli Lilly & Co (DE:LLY) report earnings?
Eli Lilly & Co (DE:LLY) is schdueled to report earning on Feb 11, 2026, Before Open (Confirmed).
What is Eli Lilly & Co (DE:LLY) earnings time?
Eli Lilly & Co (DE:LLY) earnings time is at Feb 11, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Eli Lilly & Co stock?
The P/E ratio of Eli Lilly & Co is N/A.
What is DE:LLY EPS forecast?
DE:LLY EPS forecast for the fiscal quarter 2025 (Q4) is 6.09.
